{"id":"mfolfox6-adjuvant-chemotherapy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL4650400","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It combines oxaliplatin, 5-fluorouracil, and leucovorin to inhibit DNA synthesis and function, leading to cell death in cancer cells. This regimen is used in the treatment of colorectal cancer.","oneSentence":"mFOLFOX6 is a combination chemotherapy regimen that targets rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:08.736Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of stage III colon cancer"}]},"trialDetails":[{"nctId":"NCT05174169","phase":"PHASE2, PHASE3","title":"Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-10","conditions":"Stage III Colon Cancer","enrollment":1912},{"nctId":"NCT07176182","phase":"PHASE2","title":"Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-03-01","conditions":"Rectal Cancer Patients, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":236},{"nctId":"NCT05673772","phase":"PHASE2","title":"Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyungpook National University Hospital","startDate":"2020-10-23","conditions":"Rectal Cancer","enrollment":364},{"nctId":"NCT03748485","phase":"NA","title":"Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2019-04-30","conditions":"Colorectal Cancer, Adjuvant Chemotherapy","enrollment":650},{"nctId":"NCT07328087","phase":"EARLY_PHASE1","title":"COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer","status":"RECRUITING","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV","enrollment":12},{"nctId":"NCT06052332","phase":"NA","title":"Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2024-02-07","conditions":"Locally Advanced Rectal Cancer, Older People","enrollment":230},{"nctId":"NCT02967289","phase":"PHASE3","title":"IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-27","conditions":"Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)","enrollment":792},{"nctId":"NCT04363801","phase":"PHASE2","title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"TERMINATED","sponsor":"Leap Therapeutics, Inc.","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":247},{"nctId":"NCT04625803","phase":"PHASE2","title":"Neoadjuvant Therapy for Locally Advanced Colon Cancer","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2021-01-04","conditions":"Colon Cancer, Neoadjuvant Therapy","enrollment":64},{"nctId":"NCT01804790","phase":"PHASE3","title":"Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2012-01","conditions":"Cancer of the Rectum","enrollment":461},{"nctId":"NCT05870800","phase":"PHASE2","title":"Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2025-06-15","conditions":"Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer","enrollment":28},{"nctId":"NCT02142322","phase":"PHASE2","title":"Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2004-06","conditions":"Advanced Gastric Cancer","enrollment":52},{"nctId":"NCT02494973","phase":"PHASE2, PHASE3","title":"Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2015-05-26","conditions":"Colorectal Cancer","enrollment":104},{"nctId":"NCT05954078","phase":"PHASE3","title":"Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-08-01","conditions":"High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation","enrollment":340},{"nctId":"NCT03500874","phase":"PHASE3","title":"Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2018-05-28","conditions":"Colorectal Cancer, Liver Metastases, HAI","enrollment":92},{"nctId":"NCT03135652","phase":"PHASE2","title":"Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation","status":"WITHDRAWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2017-08-01","conditions":"Radiotherapy, Colorectal Cancer, Liver Metastases","enrollment":""},{"nctId":"NCT04338191","phase":"PHASE3","title":"mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-01","conditions":"Colorectal Cancer","enrollment":638},{"nctId":"NCT00958737","phase":"PHASE3","title":"Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer","status":"UNKNOWN","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2009-05-12","conditions":"Colorectal Cancer","enrollment":2000},{"nctId":"NCT03488667","phase":"PHASE2","title":"Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2018-06-27","conditions":"Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma","enrollment":40},{"nctId":"NCT03466424","phase":"","title":"Short-course Radiotherapy (5×6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2022-08-01","conditions":"Radiation Oncology, Rectal Cancer","enrollment":9},{"nctId":"NCT05427669","phase":"PHASE3","title":"Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)","status":"NOT_YET_RECRUITING","sponsor":"Yanhong Deng","startDate":"2022-10-09","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT01307878","phase":"PHASE3","title":"New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases","status":"COMPLETED","sponsor":"Fudan University","startDate":"2012-06","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Liver Neoplasms","enrollment":320},{"nctId":"NCT05362617","phase":"PHASE3","title":"mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-01-01","conditions":"Metastatic Colorectal Cancer","enrollment":328},{"nctId":"NCT03957733","phase":"PHASE2, PHASE3","title":"Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients.","status":"UNKNOWN","sponsor":"King Abdullah Medical City","startDate":"2017-11-23","conditions":"Rectal Cancer","enrollment":338},{"nctId":"NCT04370418","phase":"PHASE2, PHASE3","title":"Neo-adjuvant Short Course Chemo-radiation Therapy in Locally Advanced Rectal Cancer Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-05-01","conditions":"Neo-adjuvant Short Course Chemo-radiotherapy in Locally Advanced Cancer Rectum","enrollment":8},{"nctId":"NCT04034355","phase":"PHASE3","title":"Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer","status":"TERMINATED","sponsor":"Egetis Therapeutics","startDate":"2019-01-07","conditions":"Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy","enrollment":301},{"nctId":"NCT05200299","phase":"PHASE2","title":"mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2022-02-01","conditions":"Colorectal Cancer","enrollment":100},{"nctId":"NCT05194878","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-12-01","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":840},{"nctId":"NCT00308516","phase":"PHASE2","title":"5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2006-03","conditions":"Rectal Cancer, Cancer of the Rectum, Colorectal Cancer","enrollment":66},{"nctId":"NCT04418895","phase":"PHASE2","title":"Neoadjuvant Therapy for Localized Rectal Adenocarcinoma","status":"WITHDRAWN","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2021-08-13","conditions":"Rectal Adenocarcinoma","enrollment":""},{"nctId":"NCT01505166","phase":"PHASE2","title":"Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases","status":"TERMINATED","sponsor":"Gradalis, Inc.","startDate":"2012-03","conditions":"Colon Cancer","enrollment":3},{"nctId":"NCT04120701","phase":"PHASE3","title":"CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-01-17","conditions":"Patients With Resected Stage II Colon Cancer","enrollment":1980},{"nctId":"NCT04145193","phase":"PHASE2","title":"Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC","status":"WITHDRAWN","sponsor":"MedImmune LLC","startDate":"2020-10-01","conditions":"Microsatellite-stable Colorectal Cancer","enrollment":""},{"nctId":"NCT04370925","phase":"PHASE3","title":"Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2020-06-04","conditions":"Colorectal Cancer","enrollment":688},{"nctId":"NCT04288999","phase":"PHASE3","title":"Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2019-10-01","conditions":"Rectal Cancer Recurrent","enrollment":110},{"nctId":"NCT02580253","phase":"PHASE2","title":"Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation","status":"WITHDRAWN","sponsor":"Zhejiang University","startDate":"2017-11-01","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT03788226","phase":"PHASE3","title":"A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2019-02-01","conditions":"Gastric Cancer Stage III","enrollment":600},{"nctId":"NCT02251977","phase":"PHASE3","title":"Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer","status":"COMPLETED","sponsor":"Yuhong Li","startDate":"2014-09","conditions":"Colorectal Cancer, Chemotherapy-induced Neutropenia","enrollment":196},{"nctId":"NCT00096278","phase":"PHASE3","title":"Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-09-15","conditions":"Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7","enrollment":2710},{"nctId":"NCT03415763","phase":"PHASE3","title":"Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy","status":"UNKNOWN","sponsor":"LI XIN-XIANG","startDate":"2018-11-05","conditions":"Rectal Neoplasms","enrollment":764},{"nctId":"NCT02965248","phase":"PHASE3","title":"Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2016-11","conditions":"Locally Advanced Colorectal Cancer","enrollment":147},{"nctId":"NCT00832299","phase":"PHASE2","title":"Neo-Adjuvant FOLFOX for Rectal Carcinoma","status":"TERMINATED","sponsor":"Beth Israel Medical Center","startDate":"2009-01","conditions":"Rectal Neoplasms","enrollment":2},{"nctId":"NCT02942563","phase":"PHASE2","title":"Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2016-11-01","conditions":"Rectal Cancer","enrollment":100},{"nctId":"NCT01749956","phase":"PHASE2","title":"5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2013-01","conditions":"Rectal Cancer","enrollment":39},{"nctId":"NCT01508000","phase":"PHASE2","title":"Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2013-06","conditions":"Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer","enrollment":44},{"nctId":"NCT02785146","phase":"PHASE3","title":"Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2016-06","conditions":"Colorectal Cancer","enrollment":230},{"nctId":"NCT02529774","phase":"PHASE2, PHASE3","title":"Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer","status":"UNKNOWN","sponsor":"Ye Xu","startDate":"2015-09","conditions":"Resected Liver Metastases From Colorectal Cancer","enrollment":432},{"nctId":"NCT02402972","phase":"PHASE3","title":"A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer","status":"UNKNOWN","sponsor":"Xu jianmin","startDate":"2015-02","conditions":"Colorectal Cancer, Metastasis","enrollment":700},{"nctId":"NCT01972503","phase":"PHASE4","title":"Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer","status":"UNKNOWN","sponsor":"Xu jianmin","startDate":"2008-06","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Liver Neoplasms","enrollment":300},{"nctId":"NCT01929499","phase":"PHASE2","title":"Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer","status":"UNKNOWN","sponsor":"Yanjuan Zhu","startDate":"2013-09","conditions":"Colonic Neoplasms","enrollment":210},{"nctId":"NCT01087658","phase":"PHASE3","title":"Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Colorectal Neoplasms","enrollment":200},{"nctId":"NCT01851941","phase":"PHASE2","title":"A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2004-10","conditions":"Advanced Gastric Cancer","enrollment":52},{"nctId":"NCT01566942","phase":"PHASE3","title":"FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2012-06","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT00988897","phase":"PHASE2","title":"Colorectal Cancer RECHALLENGE","status":"WITHDRAWN","sponsor":"Sanofi","startDate":"2009-10","conditions":"Colorectal Neoplasms","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oxaliplatin","Leucovorin","5-Fluorouracil"],"phase":"phase_3","status":"active","brandName":"mFOLFOX6 adjuvant chemotherapy","genericName":"mFOLFOX6 adjuvant chemotherapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"mFOLFOX6 is a combination chemotherapy regimen that targets rapidly dividing cancer cells. Used for Adjuvant treatment of stage III colon cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}